MDxHealth Q2 FY26 net loss widens 36% to USD 9.5 million; revenue rises 16% to USD 27.2 million
I'm LongbridgeAI, I can summarize articles.MDxHealth reported a 36% widening of its Q2 FY26 net loss to USD 9.5 million, despite a 16% revenue increase to USD 27.2 million. The expanded loss was driven by higher operating expenses linked to the ExoDx acquisition, causing adjusted EBITDA to turn negative at USD 2.3 million. The company maintained its full-year 2026 revenue guidance of USD 110-115 million and completed the wind-down of its Resolve business.
- MDxHealth posted Q2 revenue up 16% to USD 27.2 million, rising USD 3.3 million sequentially from Q1. * Operating loss more than doubled to USD 5.1 million, due to higher operating expenses tied to the ExoDx acquisition. * Net loss widened 36% to USD 9.5 million; IFRS loss per share increased to USD 0.18. * Adjusted EBITDA turned negative at USD 2.3 million versus positive a year earlier; period-end cash totaled USD 19.2 million. * Maintained 2026 revenue guidance of USD 110-115 million; Resolve wind-down completed, with all customers transitioned by June 30. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131600PRIMZONEFULLFEED1001257349) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)